Rise of pharmaceutical nationalism?
Queen Mary Intellectual Property Research Institute’s Duncan Matthews asks whether the US stance on tackling Covid-19 is enlightened independence or the sign of a new protectionist era?
Duncan Matthews, Queen Mary Intellectual Property Research Institute
The recent announcement that the US will leave the World Health Organization (WHO) was presaged by news that the country
had disassociated itself from key provisions in the World Health Assembly Covid-19 Response Resolution that refer to intellectual
property rights. Yet, both announcements belie a pharmaceutical industry reliant on global supply chains and a symbiotic relationship
between the US and China.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.